Hifumi E, Ito Y, Tsujita M, Taguchi H, Uda T
Sci Rep. 2024; 14(1):12184.
PMID: 38806597
PMC: 11133420.
DOI: 10.1038/s41598-024-63116-6.
Hifumi E, Taguchi H, Nonaka T, Uda T
Proc Jpn Acad Ser B Phys Biol Sci. 2023; 99(6):155-172.
PMID: 37331814
PMC: 10319470.
DOI: 10.2183/pjab.99.010.
Nonaka T, Taguchi H, Uda T, Hifumi E
Int J Mol Sci. 2022; 23(22).
PMID: 36430828
PMC: 9697424.
DOI: 10.3390/ijms232214351.
Hifumi E, Nonaka T, Taguchi H, Uda T
Sci Rep. 2022; 12(1):19185.
PMID: 36357546
PMC: 9649737.
DOI: 10.1038/s41598-022-23689-6.
Hifumi E, Taguchi H, Nonaka T, Harada T, Uda T
RSC Chem Biol. 2021; 2(1):220-229.
PMID: 34458785
PMC: 8341958.
DOI: 10.1039/d0cb00155d.
Arylmethylene hydrazine derivatives containing 1,3-dimethylbarbituric moiety as novel urease inhibitors.
Pedrood K, Azizian H, Nazari Montazer M, Mohammadi-Khanaposhtani M, Asgari M, Asadi M
Sci Rep. 2021; 11(1):10607.
PMID: 34012008
PMC: 8134453.
DOI: 10.1038/s41598-021-90104-x.
Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives.
Parray H, Shukla S, Samal S, Shrivastava T, Ahmed S, Sharma C
Int Immunopharmacol. 2020; 85:106639.
PMID: 32473573
PMC: 7255167.
DOI: 10.1016/j.intimp.2020.106639.
A new algorithm to convert a normal antibody into the corresponding catalytic antibody.
Hifumi E, Taguchi H, Tsuda H, Minagawa T, Nonaka T, Uda T
Sci Adv. 2020; 6(13):eaay6441.
PMID: 32232151
PMC: 7096177.
DOI: 10.1126/sciadv.aay6441.
New technologies to introduce a catalytic function into antibodies: A unique human catalytic antibody light chain showing degradation of β-amyloid molecule along with the peptidase activity.
Hifumi E, Taguchi H, Toorisaka E, Uda T
FASEB Bioadv. 2020; 1(2):93-104.
PMID: 32123823
PMC: 6996398.
DOI: 10.1096/fba.1025.
Antibody-Mediated Catalysis in Infection and Immunity.
Bowen A, Wear M, Casadevall A
Infect Immun. 2017; 85(9).
PMID: 28674034
PMC: 5563562.
DOI: 10.1128/IAI.00202-17.
Effect of Helicobacter pylori infection on the link between GLP-1 expression and motility of the gastrointestinal tract.
Eda H, Fukui H, Uchiyama R, Kitayama Y, Hara K, Yang M
PLoS One. 2017; 12(5):e0177232.
PMID: 28545056
PMC: 5436696.
DOI: 10.1371/journal.pone.0177232.
A Monoclonal Antibody to Cryptococcus neoformans Glucuronoxylomannan Manifests Hydrolytic Activity for Both Peptides and Polysaccharides.
Bowen A, Wear M, Cordero R, Oscarson S, Casadevall A
J Biol Chem. 2016; 292(2):417-434.
PMID: 27872188
PMC: 5241721.
DOI: 10.1074/jbc.M116.767582.
Physiological IgM class catalytic antibodies selective for transthyretin amyloid.
Planque S, Nishiyama Y, Hara M, Sonoda S, Murphy S, Watanabe K
J Biol Chem. 2014; 289(19):13243-58.
PMID: 24648510
PMC: 4036335.
DOI: 10.1074/jbc.M114.557231.
Biochemical features of a catalytic antibody light chain, 22F6, prepared from human lymphocytes.
Hifumi E, Fujimoto N, Arakawa M, Saito E, Matsumoto S, Kobayashi N
J Biol Chem. 2013; 288(27):19558-68.
PMID: 23677996
PMC: 3707657.
DOI: 10.1074/jbc.M113.454579.
Constant domain-regulated antibody catalysis.
Sapparapu G, Planque S, Mitsuda Y, McLean G, Nishiyama Y, Paul S
J Biol Chem. 2012; 287(43):36096-104.
PMID: 22948159
PMC: 3476277.
DOI: 10.1074/jbc.M112.401075.
Beneficial catalytic immunity to abeta peptide.
Paul S, Planque S, Nishiyama Y
Rejuvenation Res. 2010; 13(2-3):179-87.
PMID: 20370602
PMC: 2946056.
DOI: 10.1089/rej.2009.0958.
Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity.
Nishiyama Y, Planque S, Mitsuda Y, Nitti G, Taguchi H, Jin L
J Biol Chem. 2009; 284(44):30627-42.
PMID: 19726674
PMC: 2781617.
DOI: 10.1074/jbc.M109.032185.
Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain.
Sapparapu G, Planque S, Nishiyama Y, Foung S, Paul S
J Biol Chem. 2009; 284(36):24622-33.
PMID: 19542217
PMC: 2782051.
DOI: 10.1074/jbc.M109.011858.